Allergic conjunctivitis secondary prevention

Jump to navigation Jump to search

Allergic conjunctivitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Allergic Conjunctivitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Allergic conjunctivitis secondary prevention On the Web

recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Allergic conjunctivitis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Allergic conjunctivitis secondary prevention

CDC on Allergic conjunctivitis secondary prevention

Allergic conjunctivitis secondary prevention in the news

Blogs on Allergic conjunctivitis secondary prevention

Directions to Hospitals Treating Allergic conjunctivitis

Risk calculators and risk factors for Allergic conjunctivitis secondary prevention

Overview

Early diagnosis and treatment constitute the secondary prevention of allergic conjunctivitis. It involves both pharmacological and non-pharmacological measures.

Secondary Prevention

Early diagnosis

The diagnosis should be confirmed and the severity assessed by a proper history and a thorough physical examination.

Treatment

Pharmacological measures[1]

The dual-activity agents are considered first-line. When symptoms and signs remain uncontrolled, a short course of topical ophthalmic steroids may be considered which might need monitoring by an eye care specialist is necessary if prescribed for longer term. Other treatments include concomitant use of nasal steroids, oral anti-histamines and/or topical ophthalmic NSAIDs. Immunotherapy, either subcutaneous or sublingual, can be considered when medical therapy is insufficient, poorly tolerated or for patient preference.

Non-pharmacological adjuncts

References

  1. Dupuis P, Prokopich CL, Hynes A, Kim H (2020). "A contemporary look at allergic conjunctivitis". Allergy Asthma Clin Immunol. 16: 5. doi:10.1186/s13223-020-0403-9. PMC 6975089 Check |pmc= value (help). PMID 31993069.
  2. 2.0 2.1 Sánchez-Hernández MC, Montero J, Rondon C, Benitez del Castillo JM, Velázquez E, Herreras JM; et al. (2015). "Consensus document on allergic conjunctivitis (DECA)". J Investig Allergol Clin Immunol. 25 (2): 94–106. PMID 25997302.
  3. Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD (2013). "An algorithm for the management of allergic conjunctivitis". Allergy Asthma Proc. 34 (5): 408–20. doi:10.2500/aap.2013.34.3695. PMID 23998237.

Template:WH Template:WS